Table II.
Association of TPX2 expression with clinicopathological characteristics of prostate cancer.
| Dataset | ||||||
|---|---|---|---|---|---|---|
| TMA dataseta | Taylor dataset | |||||
| Clinical features | Case | Mean ± SD | P-value | Case | Mean ± SD | P-value |
| Tissue | ||||||
| Benign | 7 | 2.43±1.72 | 0.019 | 29 | 5.79±0.16 | <0.001 |
| Cancer | 73 | 5.12±2.91 | – | 150 | 6.20±0.61 | – |
| Age | ||||||
| <66 | 24 | 5.17±2.88 | 0.930 | 12 | 56.18±0.57 | 0.421 |
| ≥66 | 49 | 5.10±2.95 | – | 25 | 6.29±0.75 | – |
| Serum PSA | ||||||
| <10 | – | – | – | 105 | 6.08±0.47 | 0.009 |
| ≥10 | – | – | – | 42 | 6.37±0.63 | – |
| Gleason score | ||||||
| ≤7 | – | – | – | 117 | 6.05±0.44 | 0.004 |
| ≥8 | – | – | – | 22 | 6.59±0.77 | – |
| Pathological stage | ||||||
| I–II | 43 | 4.26±2.37 | 0.002 | 86 | 6.03±0.41 | 0.007 |
| III–IV | 27 | 6.63±3.25 | – | 55 | 6.30±0.66 | – |
| TNM stage | ||||||
| ≤T2A | 45 | 4.16±2.25 | 0.001 | 135 | 6.14±0.55 | 0.028 |
| ≥T2B | 27 | 6.78±3.22 | – | 10 | 6.55±0.76 | – |
| Metastasis | ||||||
| No | – | – | – | 122 | 6.02±0.37 | <0.001 |
| Yes | – | – | – | 28 | 6.96±0.81 | – |
| PSA rise following treatment | ||||||
| Negative | – | – | – | 104 | 6.01±0.37 | 0.001 |
| Positive | – | – | – | 36 | 6.46±0.73 | – |
| Overall survival | ||||||
| Alive | – | – | – | 131 | 6.46±0.73 | 0.002 |
| Succumbed | – | – | – | 19 | 6.90±0.96 | – |
a
Data correspond with immunoreactive score from immunohistochemical analysis; TMA, tissue microarray; PSA, prostate serum antigen; TNM, Tumor-Node-Metastasis; SD, standard deviation; TPX2, Targeting protein for Xenopus kinesin-like protein 2.